SCHEMBL7262995

SCHEMBL7262995

O=C1OC(c2ccccc2)C(c2ccccc2)N(C(=O)O)C1Cc1cccc(I)c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 4/20 0.35
FAAH O00519 1/20 0.33
SLC18A3 Q16572 2/20 0.32
DRD2 P14416 1/20 0.32
DRD1 P21728 1/20 0.32
DRD4 P21917 1/20 0.32
DRD5 P21918 1/20 0.32
DRD3 P35462 1/20 0.32
LMNA P02545 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
RECQL P46063 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
MDM2 Q00987 2/20 0.31
MAOB P27338 1/20 0.31
CYP19A1 P11511 1/20 0.31
CHRM3 P20309 1/20 0.31
MMP2 P08253 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6835149 0.87 LMNA (0.34) SIGMAR1FAAHLMNACYP1A2CYP2C9
SCHEMBL9236157 0.84 MGAM (0.34) LMNACYP1A2CYP2C9CYP2C19RECQL
SCHEMBL7898909 0.82 S1PR3 (0.39)
SCHEMBL7898908 0.82 MDM2 (0.34) MDM2
SCHEMBL6063753 0.73 ELANE (0.36) SMN1; SMN2NPSR1MDM2
SCHEMBL6063582 0.73 ELANE (0.36) SMN1; SMN2NPSR1MDM2
SCHEMBL7892968 0.73 ABCB1 (0.40)
SCHEMBL7892970 0.73 ABCB1 (0.40)
SCHEMBL8990837 0.73 MDM2 (0.42) LMNASMN1; SMN2MDM2
SCHEMBL9238321 0.72 PTGDR2 (0.31) DRD2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0728018-B1 New enzymes and prodrugs for ADEPT WELLCOME FOUND (GB) 2003-08-06 EP disclosed
US-6319702-B1 NUCLEOTIDE SEQUENCS CODING AN ENZYMATIC POLYPEPTIDE AND CELL TARGETING COMPOUND; FOR USE IN TREATMENT OF CANCER GLAXO WELLCOME, INC. 2001-11-20 US disclosed
US-6140100-A CONJUGATE POLYPEPTIDE WHICH IS TISSUE PREFERENTIAL; ANTICARCINOGENIC AGENTS GLAXO WELLCOME INC. (US) 2000-10-31 US disclosed
EP-0728018-A1 THERAPY THE WELLCOME FOUNDATION LIMITED (GB) 1996-08-28 EP disclosed
WO-1995013095-A2 THERAPY THE WELLCOME FOUNDATION LIMITED (GB) 1995-05-18 WO disclosed